FDA approves first standalone nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
Hosted on MSN14m
FDA Clears Spravato For Monotherapy Depression Treatments
The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
Healio34m
FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
WCCB56m
FDA approves standalone nasal spray for depression
A new nasal drug has been approved to treat depression. The drug Spravato  is a nasal spray made by Johnson and Johnson.